Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
OR2805 is a human IgG1 antibody that targets and binds to CD163 expressed on tumor associated macrophages, potentially resulting in an enhanced antitumor immune response, increased activation and proliferation of T lymphocytes, and T-cell mediated tumor cell death (Cancer Res 2021;81(13_Suppl):Abstract nr 1719).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Nivolumab + OR2805||Nivolumab OR2805||0||1|
|OR2805 + Pembrolizumab||OR2805 Pembrolizumab||0||1|